Prosecution Insights
Last updated: April 19, 2026
Application No. 18/751,030

SUPPORT STRUCTURES FOR INTRAVASCULAR BLOOD PUMPS

Non-Final OA §102§103§DP
Filed
Jun 21, 2024
Examiner
TEIXEIRA MOFFAT, JONATHAN CHARLES
Art Unit
3700
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Procyrion Inc.
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
2y 9m
To Grant
81%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
222 granted / 312 resolved
+1.2% vs TC avg
Moderate +10% lift
Without
With
+9.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
569 currently pending
Career history
881
Total Applications
across all art units

Statute-Specific Performance

§101
5.2%
-34.8% vs TC avg
§103
45.0%
+5.0% vs TC avg
§102
23.5%
-16.5% vs TC avg
§112
21.9%
-18.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 312 resolved cases

Office Action

§102 §103 §DP
DETAILED ACTION Applicant's election without traverse of Group 2 by Paul Stellman dated 9/15/25 is acknowledged. Claims 2-7 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Group, there being no allowable generic or linking claim. The examiner considers the amendment to claim 2 does not place Claims 2-7 under the elected Group because the sheath of Group 2 is not an obvious variant of the tether of Group 1. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 8-9 and 11-13 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 2-7, 9-11, 13-15 of U.S. Patent No. 11351359. Although the claims at issue are not identical, they are not patentably distinct from each other because both disclose a pump in a housing with struts contacting a blood vessel and having inflection points. Claims 8-9 and 11-13 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-3 and 10-18 of U.S. Patent No. 11471665. Although the claims at issue are not identical, they are not patentably distinct from each other because both disclose a pump in a housing with struts contacting a blood vessel and having inflection points. Claims 8-9 and 11-13 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4, 6-8, 10-15, and 17-25 of U.S. Patent No. 11697017. Although the claims at issue are not identical, they are not patentably distinct from each other because both disclose a pump in a housing with struts contacting a blood vessel and having inflection points. Claims 8-9 and 11-13 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5, 7-8, 10-16, 18-19, 21-23, 25-31, and 34-35 of U.S. Patent No. 12017060. Although the claims at issue are not identical, they are not patentably distinct from each other because both disclose a pump in a housing with struts contacting a blood vessel and having inflection points. Therefore, the claims of each of the preceding patents anticipate the claims of the current application. Claims 8-9 and 11-13 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 2-4 and 6-17 of copending Application No. 18/165,212 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because both disclose vessel pumps with struts making intermittent contact with the vessel wall. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 8-9 and 11 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Delgado (PG Pub. 2006/0036127). Regarding Claim 8, Delgado discloses a blood flow assist system comprising: a pump (see pump 110; Fig. 4; par. 33) comprising: an impeller (see impeller 115) disposed in a pump housing (see housing 114); and a strut (see support member 121) comprising a first end disposed at or coupled with the pump housing (see Fig. 4), a second end (see end 122) opposite the first end, and an inflection zone (see hook 123) disposed between the first end and the second end, the second end elastically deflectable toward and away from a longitudinal axis of the pump (see Fig. 3 and 4), a free state of the strut spacing the second end thereof away from the longitudinal axis of the pump (see Fig. 4), the second end of the strut configured to engage a wall of the blood vessel (see wall surface 98’ of aorta 98; par. 34); and a sheath (see sheath 140) comprising an inner wall configured to be disposed over the pump and to deflect the strut between the first and the second end thereof (see Fig. 3); wherein the inflection zone is configured such that when the strut is deflected by the inner wall of the sheath, the second end of the strut is spaced away from the inner wall of the sheath (see inward curve of 121 in Fig. 3). Regarding Claim 9, Delgado discloses wherein the second end of the strut comprises a hook (see hook 123). The examiner considers the inflection zone is the curve that produces the hook. Regarding Claim 11, Delgado discloses further comprising a tether (see wire 117) coupled with a first end of the pump, the tether comprising an electrical conveyance comprising a conductor configured to convey current to and from a source (see battery; par. 41) connectable to a proximal end of the electrical conveyance (see par. 40). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 10, 12, and 13 is/are rejected under 35 U.S.C. 103 as being unpatentable over Delgado (PG Pub. 2006/0036127) in view of Najafi et al. (PG Pub. 2011/0303229). Regarding Claim 10, Delgado does not disclose an S-shaped inflection zone. Najafi discloses a similar device having struts (see arms 26) implanted within a blood vessel (see par. 38) wherein the inflection zone comprises an S-connection between a first span of the strut and a second span of the strut, the first span and the second span being disposed along parallel trajectories (see modified Fig. 1 below and par. 21). PNG media_image1.png 600 585 media_image1.png Greyscale It would have been obvious to one of ordinary skill in the art at the time of the invention to shape the arms in this way because Najafi teaches it allows for smooth corners and edges (see par. 30) for vessel contact. Regarding Claim 12, Delgado does not disclose a convex contact pad at the end of the strut. Najafi discloses convex contact pads (see surfaces 36; par. 38) at a distal portion of the strut, the convex contact pads configured to contact a blood vessel wall to maintain spacing of the device housing from a blood vessel wall (see par. 24). It would have been obvious to one of ordinary skill in the art at the time of the invention to include convex contact pads at the ends of the struts because Najafi teaches they help to navigate blood vessel curvature without causing damage to the walls (see par. 38). Regarding Claim 13, Najafi further discloses wherein a major lateral dimension of the at least a portion of the strut is less than a major lateral dimension of the device housing (see sheath 16 of catheter 14; see modified Fig. 5 below). It would have been obvious to one of ordinary skill in the art at the time of the invention o make the lateral dimension of the strut less than a lateral dimension of the housing for an easy, low-profile deployment (see par. 18-19 and 31). The examiner considers the lateral dimension of the strut in closed position is necessarily less than the lateral dimension of the housing because it must fit within the housing during deployment. Furthermore, the claim only requires “a portion” of the strut to be less than the lateral dimension of the housing in which case even the tiniest portion of the strut would read on the claim. PNG media_image2.png 710 300 media_image2.png Greyscale Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to NATASHA PATEL whose telephone number is (571)272-5818. The examiner can normally be reached 9-5 M-F Eastern. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Unsu Jung can be reached at (571) 272-8506. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /N.P/Examiner, Art Unit 3792 /UNSU JUNG/Supervisory Patent Examiner, Art Unit 3792
Read full office action

Prosecution Timeline

Jun 21, 2024
Application Filed
Nov 21, 2025
Non-Final Rejection — §102, §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12350762
SYSTEMS AND METHODS FOR HEIGHT CONTROL IN LASER METAL DEPOSITION
2y 5m to grant Granted Jul 08, 2025
Patent 12349847
MOP HEAD AND SELF-WRINGING MOP APPARATUS AND ASSEMBLY AND METHOD OF WRINGING A MOP
2y 5m to grant Granted Jul 08, 2025
Patent 12352306
Workpiece Support For A Thermal Processing System
2y 5m to grant Granted Jul 08, 2025
Patent 12350227
BUBBLE MASSAGE FLOAT APPARATUS AND METHOD
2y 5m to grant Granted Jul 08, 2025
Patent 12343473
METHOD AND APPARATUS FOR TREATING HYPERAROUSAL DISORDER
2y 5m to grant Granted Jul 01, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
81%
With Interview (+9.9%)
2y 9m
Median Time to Grant
Low
PTA Risk
Based on 312 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month